

Who can join this study?

To be in this study, you will need to meet certain requirements:

- Be 18 years of age or older
- Have a diagnosis of prostate cancer
- Be willing to comply with all study requirements and restrictions
- Be willing and able to complete surveys during the study
- Plan to receive treatment with ORGOVYX® (relugolix) for at least four (4) months

You will **not** be able to participate if you:

- Have had surgery to remove both testicles as a treatment for your prostate cancer
- Have medical or mental conditions that may prevent you from completing the study

How will I agree to participate?

Staff at the study site will explain the study to you. An informed consent form will also explain the study in writing. This form will help you understand the study and give you the information you need to help decide whether you should participate.

You will formally agree by signing and dating the informed consent form.

How many people will be in the study?

This study will include a total of up to 1000 men with prostate cancer.

Where will it be conducted?

The study will be conducted at selected clinical sites in the United States.

Can I decide to stop participating?

Participation in this study is voluntary. You can stop participating at any time.

Contact your healthcare provider to discuss whether participating in this study is right for you.

Doctor's Name:	Dr. Nilay Gandhi (PI)
Address:	Woodbridge: 2296 Opitz Blvd. Suite 350 Woodbridge, VA. 22191 Alexandria: 1800 N. Beauregard St. Suite 300 Alexandria, VA. 22311
Phone:	703.680.2111
Email:	jvegerano@potomacurology.com

Scan the QR code or visit clinicaltrials.gov/ct2/show/NCT05467176 to learn more about this study.



© 2022 Myovant Sciences SMRC-0000



MVT-601-058

The OPTYX Prostate Cancer Registry

A Multi-Center, Prospective, Observational Study of Patients Being Treated with ORGOVYX®



What is ORGOVYX® (relugolix)?

Relugolix is an oral treatment for advanced prostate cancer.

Relugolix 120 mg has been approved by the United States Food and Drug Administration (FDA) for the treatment of adult patients with advanced prostate cancer.

How does it work?

Relugolix is a type of drug called a GnRH receptor antagonist. It lowers the amount of a hormone called testosterone in your body. Most prostate cancer cells need testosterone to grow.

Why is this study being done?

This large study will help to learn more about how relugolix works in real-world treatment.

What will I need to do?



You will continue with appointments as decided by your doctor.



You will be asked to complete a survey about how treatment affects your life. The survey will ask about your overall health, comfort, and happiness.



Another survey will ask how often you remember or forget to take your medicine.

You can complete the surveys online (at home) or on paper at the doctor's office.



How long will I be in this study?

Up to 5 YEARS

If your treatment with relugolix ends, you will be asked to follow up for up to 2 years after ending treatment.



How often will I fill out surveys?

If you participate, you will be asked to fill out surveys regularly:

- When you join the study
- 3 months after you join
- 6 months after you join
- Every 6 months for up to 5 years